paclitaxel + dexamethasone

Paclitaxel + dexamethasone is a combination regimen used in oncology, wherein **paclitaxel**, a taxane-class mitotic inhibitor, is administered together with **dexamethasone**, a synthetic glucocorticoid corticosteroid. Paclitaxel acts by stabilizing microtubules and thereby inhibiting cell division, leading to apoptosis in rapidly dividing cancer cells. Dexamethasone in this combination primarily functions as a premedication to reduce the incidence and severity of **hypersensitivity reactions** associated with paclitaxel, and to manage chemotherapy-related side effects such as nausea and inflammation[1][2][5][6][7]. Dexamethasone may also offer ancillary metabolic protection against transient hyperglycemia induced by paclitaxel[5]. The regimen is not marketed as a fixed-dose combination product but is widely used as standard supportive care in various cancer treatment protocols—including breast, ovarian, lung, pancreatic, Kaposi's sarcoma, and other solid tumors—where paclitaxel is indicated[3][4].

Brand names

Taxol + dexamethasoneAbraxane + dexamethasone

Other names

paclitaxel combination with dexamethasonepaclitaxel plus dexamethasone